NEW YORK (GenomeWeb News) – HandyLab said this week that Qiagen has licensed the firm's extraction technology for use in the sample preparation part of its human papillomavirus assays.

Ann Arbor, Mich.-based HandyLab said its extraction technology would be used with the HPV molecular diagnostic tests on Qiagen's QIAensemble and QIAsymphony random access platforms. Financial and other terms of the license were not disclosed.

HandyLab is a privately-held molecular diagnostics company developing products for the decentralization of nucleic acid testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.